Diagnostic and Prognostic Markers in Low-Grade Gliomas
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 135
- Locations
- 38
- Primary Endpoint
- Levels of PCNA, Ki-67 (MIB-1), or mutated p53 by immunostaining with monoclonal antibodies
Study Overview
Brief Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at tissue and blood samples from patients with low-grade glioma.
Detailed Description
OBJECTIVES:
- Evaluate the diagnostic and prognostic relevance of alterations of specific chromosomes and chromosomal regions including 7, 9p, 10p, 10q, 13q, 17p, 17q, 19q, 22q, X, and Y, using PCR analysis of microsatellite repeats and FISH.
- Evaluate the diagnostic and prognostic relevance of DNA ploidy by flow cytometric analysis; compare with ploidy determination by FISH.
- Assess the diagnostic and prognostic relevance of various markers of cellular proliferation and cellular function including flow cytometric determination of %S-phase, %G2M, and immunohistochemical evaluation of PCNA, Ki-67, and p53.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Retrospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Levels of PCNA, Ki-67 (MIB-1), or mutated p53 by immunostaining with monoclonal antibodies
Time Frame: baseline
DNA ploidy by FISH and flow cytometry
Time Frame: baseline
Alterations in chromosomes 7, 9p, 10, 17, 19q, X, or Y as determined by FISH
Time Frame: baseline
Loss of chromosomal materials in chromosomes 9p, 10, 13, 17, or 22 by PCR analysis
Time Frame: baseline
Percentage of cells in S-phase or G2M-phase as measured by flow cytometry
Time Frame: baseline
Secondary Outcomes
No secondary outcomes reported